Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

Metastatic colorectal cancer (mCRC) remains a leading cause of cancer-related mortality, emphasizing the need for effective later-line therapies. Fruquintinib, a selective vascular endothelial growth factor receptor (VEGFR)1-3 inhibitor, has emerged as a promising option for refractory mCRC. This systematic review and meta-analysis evaluates its efficacy and safety, both as monotherapy and in combination with programmed death-1 (PD-1) inhibitors.

Methods

Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic search was conducted across PubMed, Embase, Online Vendor of International Databases (OVID), Cochrane Library, and ClinicalTrials.gov (2010-2025). Included studies were randomized controlled trials (RCTs)

SUBMITTER: Udaikumar J 

PROVIDER: S-EPMC12780613 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature